Download PDF
Thromb Haemost 1987; 57(01): 097-101
DOI: 10.1055/s-0038-1651070
Original Articles
Schattauer GmbH Stuttgart

Effects of an Enzymatically Depolymerized Heparin as Compared with Conventional Heparin in Healthy Volunteers

Thomas Mätzsch
*   The Department of Surgery, General Hospital, Malmö, Sweden
,
David Bergqvist
*   The Department of Surgery, General Hospital, Malmö, Sweden
,
Ulla Hedner
**   The Novo Research Institute, Copenhagen, Denmark
,
Per Østergaard
**   The Novo Research Institute, Copenhagen, Denmark
› Author Affiliations
Further Information

Publication History

Received 11 September 1986

Accepted after revision 27 November 1986

Publication Date:
06 July 2018 (online)

Also available at
  PDF Download  Permissions and Reprints

Summary

A low molecular weight heparin (LMW-heparin) with a mean molecular weight of 4900 dalton was prepared by controlled enzymatic depolymerization of conventional porcine mucosal heparin. The effects of 2,500, 5,000 and 10,000 U (Xal; 29,58 and 116 mg) on factor Xa inhibition (Xal), factor Ila inhibition (Hal), APTT, AT III and platelet count were compared to those of 5,000 U (Xal; 26 mg) of conventional heparin given s. c. to 6 healthy volunteers. 5,000 U (Xal; 58 mg) of LMW-heparin was given i. v. A dose related response with regard to the Xal and the Ila-inhibitory activities with peak values at 4 hours after the s. c. injections was obtained. An increase of the Xal/IIal ratio over the time after injection was seen only after i. v. administration of the LMW-heparin. The APTT was only slightly prolonged and remained within normal range after s. c. injection. AT III and platelet counts were unaffected. The biological half life of the LMW-heparin was 111 minutes if assayed by Xa inhibition, 76 minutes if assayed by Ila inhibition and 40 minutes if assayed by APTT. A strong correlation between the Xal activities obtained and body weight was seen, indicating that LMW-heparin should be administered individually according to body weight.

Keywords

Heparin - Low molecular weight heparin - Pharmakokinetics - Enzymatic depolymerization
 

  • References

  • 1 Johnson EA, Mulloy B. The molecular weight range of mucosal heparin preparations. Carbohydrate Res 1966; 51: 119-127
    PubMedSearch in Google Scholar
  • 2 Laurent TC. Studies on fractionated heparin. Arch Biochem Biophys 1961; 92: 224-231
    CrossrefPubMedSearch in Google Scholar
  • 3 Lasker SE, Stivala SS. Physicochemical studies of fractionated bovine heparin I. Arch Biochem Biophys 1966; 115: 360-372
    CrossrefPubMedSearch in Google Scholar
  • 4 Cifonelli JA. The relationship of molecular weight, and sulphate content and distribution to anticoagulant activity of heparin preparations. Carbohydrate Res 1974; 37: 145-154
    CrossrefPubMedSearch in Google Scholar
  • 5 Andersson L-O, Barrowcliffe TW, Holmer E, Johnson EA, Sims G EC. Anticoagulant properties of heparin fractionated by affinity chromatography on matrix-bound antithrombin-III and by gel filtration. Thromb Res 1976; 9: 575-583
    CrossrefPubMedSearch in Google Scholar
  • 6 Andersson L-O, Barrowcliffe TW, Holmer E, Johnson EA, Soderstrom G. Molecular weight dependency of the heparin potentiated inhibition of thrombin and activated factor X effect of heparin neutralization in plasma. Thromb Res 1979; 15: 531-541
    CrossrefPubMedSearch in Google Scholar
  • 7 Holmer E, Kurachi K, Soderstrom G. The molecular weight dependence of the rate enhancing effect of heparin on the inhibition of thrombin, FXa, FIXa, FXIa, FXIIa and kallikrein by antithrombin. Biochem J 1981; 193: 395-400
    CrossrefPubMedSearch in Google Scholar
  • 8 Ockelford PA, Carter CJ, Hirsh J. The lack of relationship between anti-Xa activity and antithrombotic activity of low molecular weight heparin. Thromb Haemostas 1981; 46: 116 (Abstr)
    PubMedSearch in Google Scholar
  • 9 Thomas DP, Merton RE, Barrowcliffe TW, Thunberg L, Lindahl U. Effects of heparin oligosaccharides with high. affinity for antithrombin III in experimental thrombosis. Thromb Haemostas 1982; 47: 244-248
    PubMedSearch in Google Scholar
  • 10 Buchanan MR, Boneu B, Ofosu F, Hirsh J. The relative importance of thrombin inhibition and factor Xa inhibition to the antithrombotic effects of heparin. Blood 1985; 65: 198-201
    PubMedSearch in Google Scholar
  • 11 Ofosu FA, Blajchman MA, Modi GJ, Smith LM, Buchanan MR, Hirsh J. The importance of thrombin inhibition for the expression of the anticoagulant activities of heparin, dermatan sulphate, low molecular weight heparin and pentosan polysulphate. Br J Haemat 1985; 60: 695-704
    CrossrefPubMedSearch in Google Scholar
  • 12 Bergqvist D, Burmark US, Frisell J, Hallbook T, Lindblad B, Risberg B, Torngren S, Wallin G. Low molecular weight heparin once daily compared with conventional low dose heparin twice daily. A prospective double-blind multicenter trial on prevention of postoperative thrombosis. Br J Surg 1986; 73: 204-208
    CrossrefPubMedSearch in Google Scholar
  • 13 Kakkar VV, Murray W JG. Efficacy and safety of low molecular weight heparin (CY 216) in preventing postoperative venous thromboembolism: a co-operative study. Br J Surg 1985; 72: 786-791
    CrossrefPubMedSearch in Google Scholar
  • 14 Kakkar VV, Djazaeri B, Fok J, Fletcher M, Scully MF, Westwick J. Low molecular weight heparin and prevention of postoperative deep vein thrombosis. Br Med J 1982; 284: 375-379
    CrossrefPubMedSearch in Google Scholar
  • 15 Schmitz-Huebner U, Biinte H, Freise G, Reers B, Riischemeyer C, Scherer R, Schulte H, van der Loo J. Clinical efficacy of low molecular weight heparin in postoperative thrombosis prophylaxis. Klin Wochenschr 1984; 62: 349-353
    CrossrefPubMedSearch in Google Scholar
  • 16 Massonet-Castel S, Pelissier E, Dreyfus G, Deloche G, Abry B, Guiburt P, Terrier E, Passelecq JM, Jaulmes B, Carpentier A. Low molecular weight heparin in extra corporeal circulation. Lancet 1984; 1: 1182
    PubMedSearch in Google Scholar
  • 17 Barrowcliffe TW, Curtis AD, Tomlinson TP, Hubbard AR, Johnson EA, Thomas DP. Standardization of low molecular weight heparins: A collaborative study. Thromb Haemostas 1985; 54: 675-679
    PubMedSearch in Google Scholar
  • 18 Beermann B, Lahnborg G. Pharmacokinetics of heparin in healthy and obese subjects and in combination with dihydroergotamine. Thromb Haemostas 1981; 45: 24-26
    PubMedSearch in Google Scholar
  • 19 Cipolle RJ, Seifert RD, Neilan BA, Zaske DE, Haus E. Heparin kinetics: Variable related to disposition and dosage. Clin Pharmacol Ther 1981; 29: 387-393
    CrossrefPubMedSearch in Google Scholar
  • 20 Brozovic M, Sterling Y, Abbosh J. Plasma heparin levels after low dose subcutaneous heparin in patients undergoing hip replacement. Br J Haematol 1975; 31: 461-466
    CrossrefPubMedSearch in Google Scholar
  • 21 Cochetto DM, Bjornsson TD. Progress toward and understanding of the anticoagulant effect and pharmacokinetics of heparin. Pharm International 1984; jan: 7-11
    PubMedSearch in Google Scholar
  • 22 Thomas DP, Barrowcliffe TW, Merton RE, Stocks J, Dawes J, Pepper DS. In vivo release of anti-Xa clotting activity by a heparin analogue. Thromb Res 1980; 17: 831-840
    CrossrefPubMedSearch in Google Scholar
  • 23 Nilsson B, Bergqvist D, Hedner U, Pedersen PC, Ostergaard PB. Effects of low molecular weight heparins (LMWH) prepared by three different methods on experimental thrombosis and haemostasis in rabbits. Thromb Haemostas 1985; 54: 31 (Abstr)
    PubMedSearch in Google Scholar
  • 24 Nilsson IM. Haemorrhagic and thrombotic diseases. Wiley & Sons Ltd; London: 1974
  • 25 Teien AN, Lie M, Abildgaard U. Assay of heparins in plasma using a chromogenic substrate for activated factor X. Thromb Res 1976; 8: 549-553
    PubMedSearch in Google Scholar
  • 26 Odegaard OR, Lie M, Abildgaard U. Heparin co-factor activity measured with an amidolytic method. Thromb Res 1975; 6: 287-294
    CrossrefPubMedSearch in Google Scholar
  • 27 Jacques LB. Heparins-anionic polyelectrolyte drugs. Pharmacological Reviews 1979; 31: 99-166
    PubMedSearch in Google Scholar
  • 28 Levy SW, Jacques LB. Appearance of heparin antithrombin active chains in vivo after injection of commercial heparin and in anaphylaxis. Thromb Res 1978; 13: 429-441
    CrossrefPubMedSearch in Google Scholar
  • 29 Bergqvist D, Hedner U, Sjorin E, Holmer E. Anticoagulant effects of two types of low molecular weight heparin administered subcutaneously. Thromb Res 1983; 32: 381-391
    CrossrefPubMedSearch in Google Scholar
  • 30 Fareed J, Kumar A, Walenga JM, Emanuele RM, Williamson K, Hoppensteadt D. Antithrombotic actions and pharmacokinetics of heparin fractions and fragments. Nouv Rev Fr Hematol 1984; 26: 267-275
    PubMedSearch in Google Scholar
  • 31 Bara L, Billaud E, Gramond G, Kher A, Samama M. Comparative pharmacokinetics of a low molecular weight heparin (PK 10169) and unfractionated heparin after intravenous and subcutaneous administration. Thromb Res 1985; 39: 631-636
    CrossrefPubMedSearch in Google Scholar
  • 32 Ly B, Arnesen KE, Holm HA, Handeland GE, Abildgaard U. Subcutaneous LMW or unfractionated heparin in deep vein thrombosis: A randomized double-blind study with dose adjustments according to heparin concentrations in plasma. Thromb Haemostas 1985; 54: 91 (Abstr)
    PubMedSearch in Google Scholar